JPWO2023060188A5 - - Google Patents
Info
- Publication number
- JPWO2023060188A5 JPWO2023060188A5 JP2024520924A JP2024520924A JPWO2023060188A5 JP WO2023060188 A5 JPWO2023060188 A5 JP WO2023060188A5 JP 2024520924 A JP2024520924 A JP 2024520924A JP 2024520924 A JP2024520924 A JP 2024520924A JP WO2023060188 A5 JPWO2023060188 A5 JP WO2023060188A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition
- monomeric
- construct
- terminus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163253893P | 2021-10-08 | 2021-10-08 | |
| US63/253,893 | 2021-10-08 | ||
| US202263328525P | 2022-04-07 | 2022-04-07 | |
| US63/328,525 | 2022-04-07 | ||
| PCT/US2022/077690 WO2023060188A1 (en) | 2021-10-08 | 2022-10-06 | Activatable cytokine constructs and combination methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024538706A JP2024538706A (ja) | 2024-10-23 |
| JPWO2023060188A5 true JPWO2023060188A5 (https=) | 2025-10-10 |
| JP2024538706A5 JP2024538706A5 (https=) | 2025-10-10 |
Family
ID=84272320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024520924A Pending JP2024538706A (ja) | 2021-10-08 | 2022-10-06 | 活性化可能サイトカイン構成体及び併用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20230192798A1 (https=) |
| EP (1) | EP4412635A1 (https=) |
| JP (1) | JP2024538706A (https=) |
| KR (1) | KR20240099172A (https=) |
| AU (1) | AU2022360371A1 (https=) |
| CA (1) | CA3233707A1 (https=) |
| IL (1) | IL311972A (https=) |
| MX (1) | MX2024004301A (https=) |
| TW (1) | TW202334185A (https=) |
| WO (1) | WO2023060188A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024353718A1 (en) * | 2023-09-25 | 2026-04-09 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
| WO2025195305A1 (en) * | 2024-03-16 | 2025-09-25 | Vibrant Pharma Limited | Multispecific antigen binding proteins and uses thereof |
| CN120932734B (zh) * | 2025-10-13 | 2026-01-30 | 良渚实验室 | 利用中介序列msa与扩散掩码机制的肽序列生成模型及生成方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3788058T2 (de) | 1986-08-28 | 1994-04-21 | Teijin Ltd | Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung. |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US20060024272A1 (en) | 2004-07-29 | 2006-02-02 | Large Scale Biology Corporation | C-terminally truncated interferon |
| US20100189651A1 (en) | 2009-01-12 | 2010-07-29 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| JP5861223B2 (ja) | 2009-02-23 | 2016-02-16 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | プロタンパク質およびその使用方法 |
| US9487590B2 (en) | 2012-09-25 | 2016-11-08 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
| CA2925106C (en) | 2013-09-25 | 2023-11-14 | Cytomx Therapeutics, Inc. | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
| IL270562B (en) | 2014-01-31 | 2022-08-01 | Cytomx Therapeutics Inc | Polypeptide substrates that activate matriptase and u-plasminogen and other cleavable groups, preparations containing them and their uses |
| RS59340B1 (sr) | 2014-11-06 | 2019-10-31 | Hoffmann La Roche | Varijante fc regiona sa modifikovanim vezivanjem za fcrn i metode upotrebe |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| CN111050803A (zh) * | 2017-06-20 | 2020-04-21 | 德克萨斯大学系统董事会 | 用于治疗癌症的干扰素前药 |
| MY205459A (en) | 2018-12-06 | 2024-10-22 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
| BR112022009110A2 (pt) * | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| JP2024511387A (ja) * | 2021-03-16 | 2024-03-13 | シートムエックス セラピューティクス，インコーポレイテッド | マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法 |
-
2022
- 2022-10-06 JP JP2024520924A patent/JP2024538706A/ja active Pending
- 2022-10-06 AU AU2022360371A patent/AU2022360371A1/en active Pending
- 2022-10-06 TW TW111138099A patent/TW202334185A/zh unknown
- 2022-10-06 KR KR1020247011973A patent/KR20240099172A/ko active Pending
- 2022-10-06 EP EP22809608.7A patent/EP4412635A1/en active Pending
- 2022-10-06 IL IL311972A patent/IL311972A/en unknown
- 2022-10-06 CA CA3233707A patent/CA3233707A1/en active Pending
- 2022-10-06 WO PCT/US2022/077690 patent/WO2023060188A1/en not_active Ceased
- 2022-10-06 US US17/938,536 patent/US20230192798A1/en not_active Abandoned
- 2022-10-06 MX MX2024004301A patent/MX2024004301A/es unknown
-
2024
- 2024-01-25 US US18/423,006 patent/US20250026801A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ashkenazi et al. | Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. | |
| US12152060B2 (en) | Interleukin-2 variants and methods of uses thereof | |
| JP7682150B2 (ja) | プロテアーゼ活性化治療剤を含む組成物および方法 | |
| AU2026200173A1 (en) | Activatable Cytokine Constructs And Related Compositions And Methods | |
| JP2024153643A5 (https=) | ||
| US7666622B2 (en) | Monomeric self-associating fusion polypeptides and therapeutic uses thereof | |
| JP4255618B2 (ja) | 単鎖二官能性糖タンパク質ホルモン | |
| JP2020156520A5 (https=) | ||
| JPWO2019204592A5 (https=) | ||
| JP2003530070A (ja) | Ｆｃ融合タンパク質としてのインターフェロン−αタンパク質の発現および搬出 | |
| US9731007B2 (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
| US10618949B2 (en) | Method and compositions for producing disulfide-linked trimeric TNF family of cytokines and their use | |
| JPWO2021207669A5 (https=) | ||
| SK2812003A3 (en) | Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrug | |
| CN109796534B (zh) | 抗il-17抗体/tnfr ecd融合蛋白及其用途 | |
| KR20080022539A (ko) | 키메라 단백질 | |
| JP2024511387A (ja) | マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法 | |
| US20180280474A1 (en) | Treatment of bile acid disorders | |
| JP2024517871A (ja) | プロテアーゼ活性化治療剤を含む組成物および方法 | |
| JP2008521426A5 (https=) | ||
| RU2007119989A (ru) | Композиции, слитые конструкции и конъюгаты plad домена | |
| JPWO2019121906A5 (ja) | Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片 | |
| JPWO2023060188A5 (https=) | ||
| RU2007117716A (ru) | Химерный белок | |
| US11472873B2 (en) | Method treating malignant ascites and metastatic pleural effusion with and disulfide-linked trimeric TRAIL |